Consulta Rápida - Psicofármacos - 1Ed.pdf

SIBUTRAMINA
MEDICAMENTOS: INFORMAÇÕES BÁSICAS
placebo in out-patients with obsessive-compulsive disorder.
Arch Gen Psych 1995; 52: 289-295.
10. March JS, Biederman J, Wolkow R, Safferman A,
Mardekian J, Cook EH, Cutler NR, Dominguez R, Ferguson J,
Muller B, Riesenberg R, Rosenthal M, Sallee FR, Wagner KD,
Steiner H.Sertraline in children and adolescents with
obsessive-compulsive disorder: a multicenter randomized
controlled trial. JAMA1998; 280 (20): 1752-6.
11. Brady K, Pearlstein T, Asnis GM, Baker D, Rothbaum B,
Sikes CR, Farfel GM.Efficacy and safety of sertraline treatment
of posttraumatic stress disorder: a randomized controlled
trial. JAMA 2000; 283 (14): 1837-44.
12. Davidson JR, Rothbaum BO, van der Kolk BA, Sikes CR,
Farfel GM.Multicenter, double-blind comparison of sertraline
and placebo in the treatment of posttraumatic stress
disorder. Arch Gen Psychiatry 2001; 58 (5): 485-92.
13. Pollack MH, Otto MW, Worthington JJ, Manfro GG,
Wolkow R.Sertraline in the treatment of panic disorder: a
flexible-dose multicenter trial. Arch Gen Psychiatry 1998;
55 (11): 1010-6.
14. Liebowitz MR, DeMartinis NA, Weihs K, Londborg PD,
Smith WT, Chung H, Fayyad R, Clary CM.Efficacy of sertraline
in severe generalized social anxiety disorder: results of a
double-blind, placebo-controlled study. J Clin Psychiatry
2003; 64 (7): 785-92.
15. Van Ameringen MA, Lane RM, Walker JR, Bowen RC,
Chokka PR, Goldner EM, Johnston DG, Lavallee YJ, Nandy S,
Pecknold JC, Hadrava V, Swinson RP.Sertraline treatment of
generalized social phobia: a 20-week, double-blind, placebocontrolled
study. Am J Psychiatry 2001; 158 (2): 275-81.
16. Rynn MA, Siqueland L, Rickels K.Placebo-controlled trial
of sertraline in the treatment of children with generalized
anxiety disorder. Am J Psychiatry 2001; 158 (12): 2008-14.
17. Glassman AH, O’Connor CM, Califf RM, Swedberg K,
Schwartz P, Bigger JT Jr, Krishnan KR, van Zyl LT, Swenson
JR, Finkel MS, Landau C, Shapiro PA, Pepine CJ, Mardekian
J, Harrison WM, Barton D, Mclvor M; Sertraline Antidepressant
Heart Attack Randomized Trial (SADHEART) Group.
Sertraline treatment of major depression in patients with
acute MI or unstable angina. JAMA 2002; 288 (6): 701-9.
18. Serebruany VL, Glassman AH, Malinin AI, Nemeroff CB,
Musselman DL, van Zyl LT, Finkel MS, Krishnan KR, Gaffney
M, Harrison W, Califf RM, O’Connor CM. Sertraline
AntiDepressant Heart Attack Randomized Trial Study Group.
Platelet/endothelial biomarkers in depressed patients treated
with the selective serotonin reuptake inhibitor sertraline after
acute coronary events: the Sertraline AntiDepressant Heart
Attack Randomized Trial (SADHART) Platelet Substudy.
Circulation 2003; 108 (8): 939-44.
19. Stahl SM. Basic Psychopharmacology of antidepressants,
part 1: antidepressants have seven distinct mechanisms of
action. J Clin Psychiatry 1998; 59 (suppl 4): 5-14.
20. McElroy SL, Casuto LS, Nelson EB, Lake KA, Soutullo CA,
Keck PE Jr, Hudson JI.Placebo-controlled trial of sertraline in
the treatment of binge eating disorder. Am J Psychiatry 2000;
157 (6): 1004-6.
21. Halbreich U, Bergeron R, Yonkers KA, Freeman E, Stout
AL, Cohen L.Efficacy of intermittent, luteal phase sertraline
treatment of premenstrual dysphoric disorder. Obstet
Gynecol 2002; 100 (6): 1219-29.
22. Freeman EW, Rickels K, Sondheimer SJ, Polansky M.
Differential response to antidepressants in women with
premenstrual syndrome/premenstrual dysphoric disorder: a
randomized controlled trial. Arch Gen Psychiatry 1999; 56
(10): 932-9.
23. Lyketsos CG, DelCampo L, Steinberg M, Miles Q, Steele
CD, Munro C, Baker AS, Sheppard JM, Frangakis C, Brandt
J, Rabins PV.Treating depression in Alzheimer disease: efficacy
and safety of sertraline therapy, and the benefits of
depression reduction: the DIADS. Arch Gen Psychiatry 2003;
60 (7): 737-46
24. Kulin NA, Pastuszak A, Sage SR, Schick-Boschetto B,
Spivey G, Feldkamp M, Ormond K, Matsui D, Stein-
Schechman AK, Cook L, Brochu J, Rieder M, Koren G.
Pregnancy outcome following maternal use of the new
selective serotonin reuptake inhibitors: a prospective
controlled multicenter study. JAMA 1998; 279 (8): 609-10.
25. Stowe ZN, Hostetter AL, Owens MJ, Ritchie JC, Sternberg
K, Cohen LS, Nemeroff CB.The pharmacokinetics of sertraline
excretion into human breast milk: determinants of infant
serum concentrations. J Clin Psychiatry 2003; 64 (1): 73-80.
26. Schneider LS, Nelson JC, Clary CM, Newhouse P, Krishnan
KR, Shiovitz T, Weihs K; Sertraline Elderly Depression Study
Group An 8-week multicenter, parallel-group, double-blind,
placebo-controlled study of sertraline in elderly outpatients
with major depression. Am J Psychiatry 2003; 160 (7): 1277-
85.
SIBUTRAMINA
PLENTY (Lab. Medley)
• Embalagens com 30 cápsulas de 10 e 15 mg.
REDUCTIL (Lab. Abbott)
• Embalagens com 30 cápsulas de 10 e 15 mg.
FARMACOCINÉTICA
E MODO DE USAR
A sibutramina, amina terciária, é um potente inibidor
da recaptação de serotonina e norepinefrina,
desenvolvida originalmente como antidepressivo,
mas com propriedades na indução de perda
de peso. Após a administração oral, a sibutramina
é bem-absorvida. Os níveis plasmáticos máximos
são obtidos 80 minutos após uma dose única oral
de 20 mg. A meia-vida do composto principal é
de 70 minutos. Os metabólitos farmacologicamente
ativos atingem a concentração máxima em
3 horas, com meias-vidas de eliminação, de 14 e
16 horas respectivamente. As concentrações plasmáticas
aumentam proporcionalmente à dose ingerida,
tendo sido demonstrada uma cinética linear
com doses tanto abaixo de 10 mg como acima
de 30 mg. 1,2
256